The estimated Net Worth of Management Group Xii, L.L.C... is at least $280 Tisíc dollars as of 8 December 2020. Management C owns over 47,619 units of Silverback Therapeutics stock worth over $279,524 and over the last 4 years Management sold SBTX stock worth over $0.
Management has made over 1 trades of the Silverback Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Management bought 47,619 units of SBTX stock worth $999,999 on 8 December 2020.
The largest trade Management's ever made was buying 47,619 units of Silverback Therapeutics stock on 8 December 2020 worth over $999,999. On average, Management trades about 47,619 units every 0 days since 2020. As of 8 December 2020 Management still owns at least 47,619 units of Silverback Therapeutics stock.
You can see the complete history of Management C stock trades at the bottom of the page.
Over the last 6 years, insiders at Silverback Therapeutics have traded over $0 worth of Silverback Therapeutics stock and bought 2,785,936 units worth $58,491,063 . The most active insiders traders include Peter A. Thompson, Thilo Schroeder a Advisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of $1,681,567. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth $100,000.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics executives and other stock owners filed with the SEC include: